Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Life Science Summit Calls For Creation of Japanese Version of FDA, NIH, OSCHR
May 19, 2008
- Bayer to Grow Twice as Fast as Market Aiming at \200 Bil. Sales: President J-L Lowinski
May 19, 2008
- Palliative Care Needed from Initial Stage of Cancer Treatment
May 5, 2008
- Nexavar to Be Transiently Excluded from DPC System
May 5, 2008
- Iressa Effective in Japanese Lung Cancer Patients
May 5, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 5, 2008
- JPMA to Propose Exemption from Price-cutting Based on Average Price Discrepancy Rate
May 5, 2008
- ONTARGET Study Eliminates Concern over CV Risk for Micardis
May 5, 2008
- MEDICAL DEVICE NEWS IN BRIEF
May 5, 2008
- CDFS Committee Recommends Restarting Supply of Heparin
May 5, 2008
- CKD Ranks with Diabetes as a National Disease
May 5, 2008
- NEW PRODUCTS／Pfizer Japan: Oral Smoking Cessation Aid Champix
May 5, 2008
- Super Tokku to Be Created to Promote Development of Advanced Healthcare Technologies
May 5, 2008
- SURVEY／One Quarter of Depression Patients Drop Out of Treatment
May 5, 2008
- PMDA Compiles Review Guide
May 5, 2008
- Employees Are BI's Most Important Asset: Chairman Banchi
May 5, 2008
- REGULATORY NEWS IN BRIEF
May 5, 2008
- Eisai Will Recover Investment in MGI Pharma by 2016: Mr Naito
May 5, 2008
- Think More about Applications of iPS Cells to Drug Discovery: Prof. Yamanaka
May 5, 2008
- Nippon Shinyaku to Enter OB-GYN Field with Lunabell
May 5, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…